Project 4;Generation of Anti-Melanoma T cells Derived From Human Embryonic Stem Cells Abstract Genetic manipulation of the human immune system is a powerful approach to combating infectious diseases and cancers. Clinically, the most common cell based therapeutic approach currently used is hematopoietic stem cell (HSC) transplantation. The possibility of stably introducing specific T cell receptors (TCRs) into stem cells to generate T lymphocytes targeting specific antigens of choice opens doors to new and exciting life-long vaccine and therapeutic strategies. Human embryonic stem cells (hESC) and the recently-described induced pluripotent stem (IPS) cells, have the potential to revolutionize transplant technology. The theoretical ability of these cells to differentiate into any cell type in the body opens the possibility of improved cell replacement, organ replacement or genetic therapies. Induced pluripotent stem cells have a particular attraction, in that they can theorefically be derived from individual patients and will thus express idenfical HLA molecules, so they would not be rejected by the patient's immune response. We have demonstrated that hESC can be induced to differentiate into cells of the T lineage, and that IPS cells also have hematopoietic potential. New genetic material introduced into these cells can be expressed throughout hematopoietic differenfiafion. Thus the potential for adaptation of these stem cells to clinical use is especially true in regards to genetic manipulation of the immune system. The possibility of using these totipotent stem cells has many advantages over the use of HSC, including ability to culture extensively and ease of genefic manipulafion, however there are many gaps in our knowledge regarding control of differentiation into specialized mature cell types. Development of model systems to optimize and study hESC and IPS generation into funcfional T cells could be very helpful for advancing our ability to genetically manipulate immune responses. This proposal will focus on pre-clinical studies optimizing the generation, from totipotent stem cells, of human T lymphocytes directed to target human melanoma, by virtue of expression of TCRs specific for melanoma anfigens. These studies will interact with other components in this Program Project to provide poof-of-principle that hESC and/or IPS can be used to manipulate the immune system to specifically target cancer by pursuing the following specific aims: 1) Develop melanoma-specific cytotoxic T cells from human embryonic and induced pluripotent stem cells;2) Determine how expression of MART-1 TCR influences thymopoietic potential of hESC and IPS cells;3) Develop T-cell specific expression systems to opfimize distribution of TCR expression in progeny of hESC and IPS. We hope that together with the other components of this Program Project we will provide important pre-clinical informafion that cancer-specific T cells can be generated from these versatile stem cells, and that this approach may have potential for treating melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA132681-05
Application #
8627566
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
5
Fiscal Year
2014
Total Cost
$321,862
Indirect Cost
$22,681
Name
California Institute of Technology
Department
Type
DUNS #
009584210
City
Pasadena
State
CA
Country
United States
Zip Code
91125
Liu, Yarong; Xiao, Liang; Joo, Kye-Il et al. (2014) In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice. Biomacromolecules 15:3836-45
Javed, Muhammad Rashed; Chen, Supin; Kim, Hee-Kwon et al. (2014) Efficient radiosynthesis of 3'-deoxy-3'-18F-fluorothymidine using electrowetting-on-dielectric digital microfluidic chip. J Nucl Med 55:321-8
Liu, Yarong; Fang, Jinxu; Joo, Kye-Il et al. (2014) Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor. PLoS One 9:e110611
Gschweng, Eric H; McCracken, Melissa N; Kaufman, Michael L et al. (2014) HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. Cancer Res 74:5173-83
Liu, Yarong; Fang, Jinxu; Kim, Yu-Jeong et al. (2014) Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity. Mol Pharm 11:1651-61
Chodon, Thinle; Comin-Anduix, BegoƱa; Chmielowski, Bartosz et al. (2014) Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 20:2457-65
Ribas, Antoni; Tumeh, Paul C (2014) The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res 20:4982-4
Gschweng, Eric; De Oliveira, Satiro; Kohn, Donald B (2014) Hematopoietic stem cells for cancer immunotherapy. Immunol Rev 257:237-49
Liu, Yarong; Joo, Kye-Il; Lei, Yuning et al. (2014) Visualization of intracellular pathways of engineered baculovirus in mammalian cells. Virus Res 181:81-91
Atefi, Mohammad; Avramis, Earl; Lassen, Amanda et al. (2014) Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 20:3446-57

Showing the most recent 10 out of 30 publications